UNSPSC 51262103: Tinazoline

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C11H11N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 88174AK70T, chemically known as 1h-indole, 3-((4,5-dihydro-1h-imidazol-2-yl)thio)-, monohydrochloride but generally known as tinazoline, which bears US NIH Compound Identifier 68818. European Medicines Agency schedules Tinazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11073MIG. The term TINAZOLINE is an International Non-Proprietary Name.

UNSPSC 51262103 Tinazoline, a Commodity code, shows little relevant recent activity. The two most recent state and local opportunities tagged to this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI regarding direct-to-manufacturer prescription programs—do not align with tinazoline procurement. Tinazoline is a topical decongestant and antihistamine active pharmaceutical ingredient; the Seminole County solicitation targets emergency-response pharmaceuticals (naloxone) and drug deactivation equipment, while the Texas RFI explores pharmacy benefit management restructuring and direct manufacturer contracting. Neither opportunity reflects tinazoline acquisition. The code does not show a meaningful pattern of state and local procurement activity in recent solicitation records.

Without substantive opportunities in the recent posting record, no reliable characterization of issuing-body mix, geographic concentration, or representative work can be drawn. If tinazoline procurement occurs within state and local jurisdictions, it is either not tagged to this UNSPSC code or not captured in active posting records as of mid-2026. Firms pursuing tinazoline sales to state and local health departments, pharmacy programs, or emergency-response agencies should verify their target buyers' actual procurement coding practice and monitor relevant RFP/RFQ activity under pharmaceutical ingredient or OTC drug categories rather than rely on this code as a primary sourcing signal.